Disc Medicine Analyst Price Targets

Wall Street analyst price targets and consensus rating for Disc Medicine (IRON).

Price Target Range — 12 Quarters

Analyst Consensus — 10 Analysts

1S.Buy

9Buy

Consensus RatingBuy# Analysts10Avg. Consensus PT$93Upside to Avg. PT+67.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 16, 2026	Wells Fargo	Derek Archila	PT Raise	Overweight	$79→$86
Sep 10, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$100
Sep 2, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$88→$100
Aug 6, 2026	HC Wainwright & Co.	Douglas Tsao	PT Raise	Buy	$118→$120
Jun 16, 2026	Morgan Stanley	Sean Laaman	PT Raise	Overweight	$80→$85
Jun 10, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$88
May 14, 2026	Morgan Stanley	Sean Laaman	PT Raise	Overweight	$75→$80
Mar 2, 2026	Wells Fargo	Derek Archila	PT Raise	Overweight	$78→$79
Feb 27, 2026	Truist Securities	Danielle Brill	PT Cut	Buy	$114→$83
Feb 17, 2026	Stifel	Stephen Willey	PT Cut	Buy	$125→$110
Feb 17, 2026	Cantor Fitzgerald	Kristen Kluska	PT Cut	Overweight	$153→$125
Feb 17, 2026	BMO Capital	Evan David Seigerman	PT Cut	Outperform	$120→$100
Feb 17, 2026	Wedbush	David Nierengarten	PT Cut	Outperform	$110→$88
Feb 17, 2026	Wells Fargo	Derek Archila	PT Cut	Overweight	$109→$78
Dec 16, 2025	Wells Fargo	Derek Archila	PT Raise	Overweight	$91→$109
Nov 10, 2025	Truist Securities	Danielle Brill	PT Raise	Buy	$86→$114
Nov 3, 2025	Stifel	Stephen Willey	Reinstates	Buy	$125
Oct 30, 2025	Morgan Stanley	Sean Laaman	PT Raise	Overweight	$90→$115
Oct 17, 2025	Raymond James	Martin Auster	PT Raise	Strong Buy	$89→$108
Oct 17, 2025	Cantor Fitzgerald	Kristen Kluska	PT Raise	Overweight	$132→$153

More with Benzinga EdgeGet Access

Analyst Ratings News

Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday

Analysts raised targets for RAPP, ALLR, UNP and ALVO; cut targets for NU, CLLS and JBHT, with several rating upgrades and downgrades.

Avi Kapoor

PRO
Wells Fargo Maintains Overweight on Disc Medicine, Raises Price Target to $86

Wells Fargo analyst Derek Archila maintains Disc Medicine (NASDAQ:IRON) with a Overweight and raises the price target from $79 to $86.

Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Disc Medicine, Maintains $100 Price Target

Wedbush analyst David Nierengarten reiterates Disc Medicine (NASDAQ:IRON) with a Outperform and maintains $100 price target.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Disc Medicine, Raises Price Target to $100

Wedbush analyst David Nierengarten maintains Disc Medicine (NASDAQ:IRON) with a Outperform and raises the price target from $88 to $100.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Disc Medicine, Raises Price Target to $120

HC Wainwright & Co. analyst Douglas Tsao maintains Disc Medicine (NASDAQ:IRON) with a Buy and raises the price target from $118 to $120.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $85

Morgan Stanley analyst Sean Laaman maintains Disc Medicine (NASDAQ:IRON) with a Overweight and raises the price target from $80 to $85.

Benzinga Newsdesk

Disc Medicine Inc

Disc Medicine Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday

PRO
Wells Fargo Maintains Overweight on Disc Medicine, Raises Price Target to $86

PRO
Wedbush Reiterates Outperform on Disc Medicine, Maintains $100 Price Target

PRO
Wedbush Maintains Outperform on Disc Medicine, Raises Price Target to $100

PRO
HC Wainwright & Co. Maintains Buy on Disc Medicine, Raises Price Target to $120

PRO
Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $85

People Also Watch

People Also Watch

Disc Medicine Inc

Disc Medicine Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday

PROWells Fargo Maintains Overweight on Disc Medicine, Raises Price Target to $86

PROWedbush Reiterates Outperform on Disc Medicine, Maintains $100 Price Target

PROWedbush Maintains Outperform on Disc Medicine, Raises Price Target to $100

PROHC Wainwright & Co. Maintains Buy on Disc Medicine, Raises Price Target to $120

PROMorgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $85

People Also Watch

People Also Watch

PRO
Wells Fargo Maintains Overweight on Disc Medicine, Raises Price Target to $86

PRO
Wedbush Reiterates Outperform on Disc Medicine, Maintains $100 Price Target

PRO
Wedbush Maintains Outperform on Disc Medicine, Raises Price Target to $100

PRO
HC Wainwright & Co. Maintains Buy on Disc Medicine, Raises Price Target to $120

PRO
Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $85